Skip to main content
. 2018 May 15;8:150. doi: 10.3389/fcimb.2018.00150

Table 2.

Disease remission vs. recurrence in all patients.

Total: 116 patients Remission Recurrence p-value
Patients 58 58
Age 49.7 48.0 p = 0.490
Male 27 (46.6%) 30 (51.7%) p = 0.577
Female 31 (53.4%) 28 (48.3%)
Asthma 33 (56.9%) 42 (72.4%) p = 0.080
Previous ESS 32 (55.2%) 48 (82.8%) p = 0.001
Smoking
    Never 24 (41.4%) 28 (48.3%) p = 0.591
    Active 11 (19.0%) 8 (13.8%)
    Former 23 (39.6%) 22 (37.9%)
Polyposis 57 (98.3%) 51 (87.9%) p = 0.061
Race
    Caucasian 52 (89.7%) 52 (89.7%) p = 1.000
    Hispanic 3 (5.2%) 3 (5.2%)
    Asian 1 (1.7%) 1 (1.7%)
    Arabic 2 (3.4%) 2 (3.4%)
Allergies (all types) 48 (82.8%) 42 (72.4%) p = 0.182
    Seasonal 27 (46.6%) 17 (29.3%) p = 0.056
    NSAID 7 (12.1%) 16 (27.6%) p = 0.036
S. aureus (pre-ESS) 4 (7.3%) 14 (24%) p = 0.020
S. aureus (post-ESS) 7 (13.0%) 24 (47.1%) p < 0.001
P. aeruginosa (pre-ESS) 1 (1.8%) 5 (8.6%) p = 0.207
P. aeruginosa (post-ESS) 1 (1.9%) 6 (11.8%) p = 0.056
Gram negative (pre-ESS) 13 (23.6%) 12 (20.7%) p = 0.706
Gram negative (post-ESS) 6 (11.1%) 13 (25.5%) p = 0.056
SNSS (post-ESS) 4.4 5.2 p = 0.306
SNOT22 (post-ESS) 25.5 32.6 p = 0.098
Lund-Kennedy (post-ESS) 0.98 6.3 p < 0.001